Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines

Documenti analoghi

• Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
  di: Leung, Euphemia Y., et al.
  Pubblicazione: (2015)
• Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
  di: Leung, Euphemia, et al.
  Pubblicazione: (2014)
• Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
  di: Kim, Ji Eun, et al.
  Pubblicazione: (2013)
• Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs
  di: Leung, Euphemia Yee, et al.
  Pubblicazione: (2014)
• Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
  di: Leung, Euphemia, et al.
  Pubblicazione: (2011)